On Wednesday, Clearside Biomedical, Inc. (NASDAQ:CLSD) announced that the ODYSSEY Phase 2b trial of CLS-AX (axitinib injectable suspension) for neovascular age-related macular degeneration (wet AMD) ...
Source LinkOn Wednesday, Clearside Biomedical, Inc. (NASDAQ:CLSD) announced that the ODYSSEY Phase 2b trial of CLS-AX (axitinib injectable suspension) for neovascular age-related macular degeneration (wet AMD) ...
Source Link
Comments